Strategy to targeting the immune resistance and novel therapy in colorectal cancer.

摘要: Assessing the CRC subtypes that can predict outcome of colorectal cancer (CRC) in patients with immunogenicity seems to be a promising strategy develop new drugs target antitumoral immune response. In particular, disinhibition T-cell response by checkpoint blockade has shown remarkable therapeutic promise for mismatch repair (MMR) deficient CRC. this review, authors provide update molecular features and CRC, discuss role possible predictive biomarkers, illustrate modern immunotherapeutic approaches, introduce most relevant ongoing preclinical study clinical trials such as use combination therapy immunotherapy. Furthermore, work is further understand complex interactions between surveillance resistance tumor cells. As expected, if these developments fulfilled, it could effective strategies novel combinations overcome enhance effector responses, which guide clinicians toward more "personalized" treatment advanced patients.